These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7695258)

  • 1. Pharmacokinetics of the triazole antifungal agent genaconazole in healthy men after oral and intravenous administration.
    Mojaverian P; Radwanski E; Affrime MB; Cayen MN; Lin CC
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2758-62. PubMed ID: 7695258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and metabolism of genaconazole, a potent antifungal drug, in men.
    Lin C; Kim H; Radwanski E; Affrime M; Brannan M; Cayen MN
    Antimicrob Agents Chemother; 1996 Jan; 40(1):92-6. PubMed ID: 8787886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the active antifungal enantiomer, SCH 42427 (RR), and evaluation of its chiral inversion in animals following its oral administration and the oral administration of its racemate genaconazole (RR/SS).
    Kim H; Radwanski E; Lovey R; Lin CC; Nomeir AA
    Chirality; 2002 May; 14(5):436-41. PubMed ID: 11984759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.
    Schmitt-Hoffmann A; Roos B; Maares J; Heep M; Spickerman J; Weidekamm E; Brown T; Roehrle M
    Antimicrob Agents Chemother; 2006 Jan; 50(1):286-93. PubMed ID: 16377699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.
    Schmitt-Hoffmann A; Roos B; Heep M; Schleimer M; Weidekamm E; Brown T; Roehrle M; Beglinger C
    Antimicrob Agents Chemother; 2006 Jan; 50(1):279-85. PubMed ID: 16377698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
    Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetic evaluation of fluconazole in healthy volunteers].
    Shiba K; Saito A; Miyahara T
    Jpn J Antibiot; 1989 Jan; 42(1):17-30. PubMed ID: 2540363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
    Purkins L; Wood N; Ghahramani P; Greenhalgh K; Allen MJ; Kleinermans D
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2546-53. PubMed ID: 12121931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
    Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
    Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.
    Wenzler E; Ellis-Grosse EJ; Rodvold KA
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives.
    Khan JK; Montaseri H; Poglod M; Bu HZ; Zuo Z; Salama SM; Daneshtalab M; Micetich RG
    Antimicrob Agents Chemother; 2000 Apr; 44(4):910-5. PubMed ID: 10722490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posaconazole pharmacokinetics after administration of an intravenous solution, oral suspension, and delayed-release tablet to dogs.
    Kendall J; Papich MG
    Am J Vet Res; 2015 May; 76(5):454-9. PubMed ID: 25909378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients.
    Sime FB; Stuart J; Butler J; Starr T; Wallis SC; Pandey S; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1.
    Dimmitt DC; Choo YS; Martin LA; Arumugham T; Hahne WF; Weir SJ
    Biopharm Drug Dispos; 1999 Jan; 20(1):29-39. PubMed ID: 10086835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posaconazole Pharmacokinetics in Healthy Cats after Oral and Intravenous Administration.
    Mawby DI; Whittemore JC; Fowler LE; Papich MG
    J Vet Intern Med; 2016 Sep; 30(5):1703-1707. PubMed ID: 27425589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability of LCB01-0371.
    Cho YS; Lim HS; Han S; Yoon SK; Kim H; Cho YL; Nam HS; Bae KS
    Clin Ther; 2019 Jan; 41(1):92-106. PubMed ID: 30559004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.
    Schmitt-Hoffmann A; Roos B; Spickermann J; Heep M; Peterfaí E; Edwards DJ; Stoeckel K
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4885-90. PubMed ID: 19667286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, phase I, 3-way crossover study to examine the effects of food on the pharmacokinetics of single doses of 400 mg posaconazole oral suspension in healthy male Taiwanese subjects.
    Lin TY; Yang MH; Chang FY
    Ther Drug Monit; 2013 Apr; 35(2):223-7. PubMed ID: 23503449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.
    Dodds Ashley ES; Varkey JB; Krishna G; Vickery D; Ma L; Yu X; Malavade D; Goodwin M; Perfect JR; Power E
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2960-4. PubMed ID: 19433558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.